Marisa Wexler, MS,  senior science writer—

Enrollment has finished in a clinical trial testing the experimental therapy CMTX-101, which is designed to help clear out bacterial lung infections in people with cystic fibrosis (CF) and other diseases. Top-line results from the Phase 1b/2a study (NCT06159725) are expected to be announced in the first quarter…

The Cystic Fibrosis Foundation is making a new investment of up to $11 million in 4D Molecular Therapeutics (4DMT) to support the development of 4D-710, the company’s inhaled gene therapy for cystic fibrosis (CF) that is currently in clinical development. The funding, which builds on earlier support,…

The experimental anti-inflammatory therapy brensocatib was generally well tolerated in adults with cystic fibrosis (CF), according to data from a small clinical trial aimed at aiding the design of future studies of the therapy. Brensocatib’s pharmacological profile in CF patients is similar to its profile in people without CF,…

The Cystic Fibrosis Foundation has made an additional $3 million investment in Recode Therapeutics to support clinical development of RCT2100, an investigational therapy for cystic fibrosis (CF) that is currently being tested in patients who cannot take CFTR modulators. The CF Foundation had previously invested $15 million…

The Unity Fetal Risk Screen, a test that uses a pregnant person’s blood to evaluate the fetus’s risk of cystic fibrosis (CF), accurately detected all cases of CF in a study involving more than 100,000 pregnant people. The study found that most CF cases identified by the test are…

A trio of scientists is being honored for research contributions that helped lead to the development of Trikafta, a triple-drug combination medication for people with cystic fibrosis (CF). The three winners of this year’s Lasker~DeBakey Clinical Medical Research Award are Paul Negulescu, PhD, senior vice president at Vertex…

The Cystic Fibrosis Foundation is investing up to €6.5 million (about $7.6 million) to support the development of virus-based therapies to treat Pseudomonas infections in people with cystic fibrosis (CF). The funding to Snipr Biome — which plans to use gene editing technology to improve the viruses’ ability…

SPL84, an investigational inhalation therapy designed to treat cystic fibrosis (CF) caused by a specific mutation called 3849+10 kb C-to-T, was well tolerated in a Phase 2 clinical trial. Trial data also suggest that most CF patients treated with SPL84 experienced improvements in a measure of lung function, according…

The first participants have been dosed in a clinical trial that’s testing some of Sionna Therapeutics’ investigational treatments for cystic fibrosis (CF). The Phase 1 study (NCT07035990) is testing SION-451 with either SION-2222 or SION-109 in healthy volunteers, with the main goal being to evaluate the safety…

The U.S. Food and Drug Administration (FDA) has granted two new designations to CMTX-101, an antibody-based therapy Clarametyx Biosciences is developing to treat bacterial lung infections in people with cystic fibrosis (CF). The regulatory agency granted CMTX-101 fast track designation, which aims to speed the development of new…